Danaher will add Masimo’s patient monitoring solutions to its diagnostics portfolio while Spectrum and Piccolo work to bring next-generation catheter guidance technology to market.
Posted by Clare Scott, Managing Editor – Manufacturing Group
Spectrum Vascular, provider of vascular access and medication management products, announced the acquisition of Piccolo Medical, developer of catheter guidance products. The transaction deepens a partnership focused on bringing next-generation catheter guidance technology to market and marks a significant step forward in Spectrum’s mission to deliver a complete, differentiated vascular access solution to the clinical community.
Augustus Shanahan, CEO of Piccolo, will join Spectrum alongside the legacy Piccolo team. The group will advance development and commercialization of its 510(k)-cleared catheter guidance and location products, building upon an innovation roadmap more than a decade in the making. Piccolo’s real-time catheter guidance utilizes proprietary blood flow sensing technology to precisely guide catheter tip placement, eliminating the need for confirmatory chest X-rays. Piccolo completed the first successful patient placements of its next-generation Nav+ Stylet in May 2026, marking the beginning of a new era in guided vascular access.
“Joining the Spectrum team marks an exciting new chapter for Piccolo and for vascular access as a whole,” Shanahan says. “I am incredibly proud of what the Piccolo team has built over the past decade, and together with Spectrum, we now have the platform, the portfolio, and the reach to set a new standard, delivering better outcomes for patients and real economic value for the hospitals that serve them.”
“The acquisition of Piccolo Medical represents an important milestone in our mission to transform vascular access,” says Kenneth Miller, CEO of Spectrum. “By combining Piccolo’s breakthrough navigation technology with Spectrum’s vascular access portfolio and commercial reach, we are uniquely positioned to accelerate innovation, improve patient care, and redefine the standard of care for clinicians worldwide.”
Together, Piccolo and Spectrum will accelerate commercialization, deepen integration with Spectrum’s existing catheter portfolio, and scale the next-generation navigation platform.
Danaher Corp., a global science and technology innovator, has completed the acquisition of Masimo Corp., a specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
Masimo’s trusted brand, advanced sensor technology, and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher’s Diagnostics segment.
“Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach,” says Julie Sawyer Montgomery, executive vice president of Diagnostics at Danaher. “We are excited to welcome the Masimo team to Danaher.”
The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.